ViiV Healthcare, a joint venture by Pfizer and GlaxoSmithKline, has appointed Porter Novelli to manage its corporate comms account, PRWeek understands.
CVS excludes 31 drugs including Viagra from its 2016 formulary; Sanofi partners with Evotec on stem-cell treatment development; primary-care physicians may hesitate to prescribe Truvada for PrEP
Shire buys Foresight Biotherapeutics for $300 million; Novartis sold off three investigational drugs into Mereo BioPharma; new blood thinners linked to 8,000 deaths since 2010
Researchers find repeat marketing offenders in the UK and Sweden, Actavis plans to take Allergan's name and Sanofi enters an auto-immune disease collaboration.
FDA clears Novo's liraglutide for obesity; doctors' views vary on Express Scripts' hep.-C plan; Janssen, Gilead advance plans for HIV drugs.
The number of new HIV cases has held steady since the 1990s. Researchers note it is progress of a sort, but that driving numbers down requires one basic step: testing, testing, testing.
The deal will cap the monthly price some patients may pay for medications such as Atripla.
Roche backs away from Chugai but embraces InterMune, Merck rumored on track to score first PD-1 approval, a new Ebola strain may have surfaced and JNJ scoops up experimental anti-TNF.
Phase-II data show reduced hepatitis-C RNA levels among HIV-positive patients, the drugmaker shared at a medical meeting. Boehringer also released co-infection data.
The GlaxoSmithKline-Pfizer-Shionogi joint venture scored an FDA approval in August.
The Kaiser Family Foundation's just-launched website, funded by Gilead, addresses healthcare reform from a distinct perspective.
Adding Epzicom to Tivicay in a once-daily cocktail could further boost GSK's HIV franchise, and possibly chip away at Atripla's dominance.
Gilead's Striblid faces hurdle in Germany, Boehringer and Roche team up for companion diagnostic effort and Wisconsin hospital system says no to samples
CDC finds that non-Medicare adults make up the majority of preventable heart attack and stroke cases; a Facebook study shows groups can influence HIV screening; and a Shire ADHD drug gets a "no" from Germany
The GSK-Pfizer-Shionogi daily HIV medication gets the regulatory all-clear. The approval could put BMS/Gilead's best-selling daily med Atripla on the defensive.
A two-year study shows Gilead's Quad pill outpaces an older combination drug over two years, and GSK is seeking to expand its oncology presence.
Messaging around HIV testing now mixes individual concerns with community protection. Recent efforts, like those of the CDC and Greater than AIDS, try to make getting tested an empowering act.
Pharma pared back its ad spend in 2012, a baby born HIV-positive is virus-free two-and-a-half years later, and Boston Children's Hospital is making its own apps.
- Which drugmakers have the healthiest presence on social media?
- Five things for pharma marketers to know: Monday, September 26, 2016
- Uber partners with startup to take patients to the doctor
- Five things for pharma marketers to know: Tuesday, September 27, 2016
- Five things for pharma marketers to know: Wednesday, September 28, 2016
- Merck educates doctors about biosimilars, long before it will sell one in the U.S.
- 4 trends with the potential to change behavior in the patient journey
- When it comes to professional ads, print makes its comeback
- 2016 Pharma Report: All the data in one place
- What do physicians think about biosimilars?
- Drugmakers set their sights on the next potential blockbuster disease: NASH
- Five things for pharma marketers to know: Thursday, September 29, 2016
- BBDO picks up Neulasta; FCB gains Galderma and Sandoz work in the U.S.
- How to get more women in the C-suite, according to IPG, Unilever, and AOL
- Why Any Merger is the Last Resort of Lousy Marketers